Physician profile
Lin Wang
NPI 1710412085
$4,477.04
in general payments reported to CMS, 2019-2025
32 companies · $722 in 2025
The $722 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $105 · 2021: $267 · 2022: $442 · 2023: $483 · 2024: $2,458 · 2025: $722.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,686 · Travel and Lodging: $1,162 · Consulting Fee: $340 · Education: $276 · Long Term Medical Supply Or Device Loan: $199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,686.18 |
| Travel and Lodging | $1,161.81 |
| Consulting Fee | $340.00 |
| Education | $275.95 |
| Long Term Medical Supply Or Device Loan | $199.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech, INC. | $1,932.57 | 2024 | |
| Astrazeneca Pharmaceuticals Lp | $338.85 | 2023-2025 | Enhertu, Lynparza, Tagrisso |
| Novartis Pharmaceuticals Corporation | $251.34 | 2024-2025 | |
| Daiichi Sankyo INC. | $221.22 | 2021-2025 | Enhertu, Datroway |
| Adc Therapeutics America, INC. | $142.13 | 2024-2025 | |
| Aurinia Pharma U.S., INC. | $141.13 | 2022-2023 | Lupkynis |
| Takeda Pharmaceuticals U.S.A., INC. | $126.36 | 2022-2024 | Fruzaqla |
| Puma Biotechnology, INC. | $123.00 | 2021 | |
| Merck Sharp & Dohme LLC | $121.41 | 2022-2025 | Keytruda, Keytruda Qlex |
| Seagen INC. | $110.33 | 2023 | Adcetris |
| Boston Scientific Corporation | $105.14 | 2019 | |
| Abbvie INC. | $104.00 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $71.49 | 2023-2024 | |
| Agios Pharmaceuticals, INC. | $69.04 | 2025 | Pyrukynd |
| Exelixis INC. | $66.85 | 2022-2024 | Cabometyx |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $66.19 | 2021-2025 | Tecvayli |
| Pfizer INC. | $51.14 | 2022-2024 | |
| Apellis Pharmaceuticals, INC. | $42.25 | 2023-2024 | Empaveli |
| Incyte Corporation | $41.15 | 2022-2023 | Monjuvi |
| Taiho Oncology, INC. | $40.14 | 2022-2023 | |
| Eisai INC. | $39.50 | 2022-2024 | |
| Servier Pharmaceuticals LLC | $37.47 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $34.32 | 2022 | |
| Blueprint Medicines Corporation | $30.29 | 2023 | Ayvakit |
| Ardelyx, INC. | $29.11 | 2025 | Ibsrela |
| Amgen INC. | $24.59 | 2022 | |
| Pharmacyclics LLC, An Abbvie Company | $22.64 | 2023 | Imbruvica, Epkinly |
| Mirati Therapeutics, INC. | $22.23 | 2023 | Krazati |
| Kyowa Kirin, INC. | $21.72 | 2023 | Poteligeo |
| Deciphera Pharmaceuticals INC. | $19.99 | 2025 | Qinlock, Tgct |
| Secura Bio, INC. | $15.81 | 2023 | Copiktra |
| E.R. Squibb & Sons, L.L.C. | $13.64 | 2025 | Opdivo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lin Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.